openia <2,000/mm 3 <500/mm 3 - leukopenia <4,000/mm 3 <1,000/mm 3 - thrombocytopenia <100,000/mm 3 <50,000/mm 3 - anemia <11 g/dl <8 g/dl - infections - bleeding - red cell transfusions - platelet transfusions 90 52 90 17 20 7 78 16 30 14 25 2 hypersensitivity reaction b - all - severe 41 2 cardiovascular - vital sign changes c - bradycardia (n=537) - hypotension (n=532) - significant cardiovascular events 3 12 1 abnormal ecg - all pts - pts with normal baseline (n=559) 23 14 peripheral neuropathy - any symptoms - severe symptoms 60 3 myalgia/arthralgia - any symptoms - severe symptoms 60 8 gastrointestinal - nausea and vomiting - diarrhea - mucositis 52 38 31 alopecia 87 hepatic (pts with normal baseline and on study data) - bilirubin elevations (n=765) - alkaline phosphatase elevations (n=575) - ast (sgot) elevations (n=591) 7 22 19 injection site reaction 13 a based on worst course analysis. b all patients received premedication. c during the first 3 hours of infusion severe events are defined as at least grade iii toxicity. none of the observed toxicities were clearly influenced by age. disease-specific adverse event experiences first-line ovary in combination for the 1,084 patients who were evaluable for safety in the phase 3 first-line ovary combination therapy studies, table 11 shows the incidence of important adverse events. for both studies, the analysis of safety was based on all courses of therapy (6 courses for the gog- 111 study and up to 9 courses for the intergroup study). table 11. frequency a of important adverse events in the phase 3 first-line ovarian carcinoma studies percent of patients intergroup gog-111 t175/3 b c75 c (n=339) c750 c c75 c (n=336) t135/24 b c75 c (n=196) c750 c c75 c (n=213) bone marrow - neutropenia <2,000/mm 3 91 d 95 d 96 92 <500/mm 3 33 d 43 d 81 d 58 d - thrombocytopenia <100,000/mm 3e 21 d 33 d 26 30 <50,000/mm 3 3 d 7 d 10 9 - anemia <11 g/dl f 96 97 88 86 <8 g/dl 3 d 8 d 13 9 - infections 25 27 21 15 - febrile neutropenia 4 7 15 d 4 d hypersensitivity reaction - all 11 d 6 d 8 d,g 1 d,g - severe 1 1 3 d,g - d,g neurotoxicity h - any symptoms 87 d 52 d 25 20 - severe symptoms 21 d 2 d 3 d - d nausea and vomiting - any symptoms 88 93 65 69 - severe symptoms 18 24 10 11 myalgia/arthralgia - any symptoms 60 d 27 d 9 d 2 d - severe symptoms 6 d 1 d 1 - diarrhea - any symptoms 37 d 29 d 16 d 8 d - severe symptoms 2 3 4 1 athenia - any symptoms nc nc 17 d 10 d - severe symptoms nc nc 1 1 alopecia - any symptoms 96 d 89 d 55 d 37 d - severe symptoms 51 d 21 d 6 8 a based on worst course analysis. b paclitaxel (t) dose in mg/m 2 /infusion duration in hours. c cyclophosphamide (c) or cisplatin (c) dose in mg/m 2 . d p<0.05 by fisher exact test. e <130,000/mm 3 in the intergroup study. f <12 g/dl in the intergroup study. g all patients received premedication. h in the gog-111 study, neurotoxicity was collected as peripheral neuropathy and in the intergroup study, neurotoxicity was collected as either neuromotor or neurosensory symptoms. severe events are defined as at least grade iii toxicity. nc not collected. second-line ovary: for the 403 patients who received single-agent paclitaxel injection in the phase 3 second-line ovarian carcinoma study, the following table shows the incidence of important adverse events. table 12. frequency a of important adverse events in the phase 3 second-line ovarian carcinoma study percent of patients 175/3 b (n=95) 175/24 b (n=105) 135/3 b (n=98) 135/24 b (n=105) bone marrow - neutropenia <2,000/mm 3 <500/mm 3 - thrombocytopenia <100,000/mm 3 <50,000/mm 3 - anemia <11 g/dl <8 g/dl - infections 78 27 4 1 84 11 26 98 75 18 7 90 12 29 78 14 8 2 68 6 20 98 67 6 1 88 10 18 hypersensitivity reaction c - all - severe 41 2 45 0 38 2 45 1 peripheral neuropathy - any symptoms - severe symptoms 63 1 60 2 55 0 42 0 mucositis - any symptoms - severe symptoms 17 0 35 3 21 0 25 2 a based on worst course analysis. b paclitaxel dose in mg/m 2 /infusion duration in hours. c all patients received premedication. severe events are defined as at least grade iii toxicity. myelosuppression was dose and schedule related, with the schedule effect being more prominent. the development of severe hypersensitivity reactions (hsrs) was rare; 1% of the patients and 0.2% of the courses overall. there was no apparent dose or schedule effect seen for the hsrs. peripheral neuropathy was clearly dose-related, but schedule did not appear to affect the incidence. adjuvant breast for the phase 3 adjuvant breast carcinoma study, the following table shows the incidence of important severe adverse events for the 3121 patients (total population) who were evaluable for safety as well as for a group of 325 patients (early population) who, per the study protocol, were monitored more intensively than other patients. table 13. frequency a of important severe b adverse events in the phase 3 adjuvant breast carcinoma study percent of patients early population total population ac c (n=166) ac c followed by t d (n=159) ac c (n=1551) ac c followed by t d (n=1570) bone marrow e - neutropenia <500/mm 3 79 76 48 50 - thrombocytopenia <50,000/mm 3 27 25 11 11 - anemia <8 g/dl 17 21 8 8 - infections 6 14 5 6 - fever without infection 3 <1 1 hypersensitivity reaction f 1 4 1 2 cardiovascular events 1 2 1 2 neuromotor toxicity 1 1 <1 1 neurosensory toxicity 3 <1 3 myalgia/arthralgia 2 <1 2 nausea/vomiting 13 18 8 9 mucositis 13 4 6 5 a based on worst course analysis. b severe events are defined as at least grade iii toxicity. c patients received 600 mg/m 2 cyclophosphamide and doxorubicin (ac) at doses of either 60 mg/m 2 , 75 mg/m 2 , or 90 mg/m 2 (with prophylactic g-csf support and ciprofloxacin), every 3 weeks for 4 courses. d paclitaxel (t) following 4 courses of ac at a dose of 175 mg/m 2 /3 hours every 3 weeks for 4 courses. e the incidence of febrile neutropenia was not reported in this study. f all patients were to receive premedication. the incidence of an adverse event for the total population likely represents an underestimation of the actual incidence given that safety data were collected differently based on enrollment cohort. however, since safety data were collected consistently across regimens, the safety of the sequential addition of paclitaxel following ac therapy may be compared with ac therapy alone. compared to patients who received ac alone, patients who received ac followed by paclitaxel experienced more grade iii/iv neurosensory toxicity, more grade iii/iv myalgia/arthralgia, more grade iii/iv neurologic pain (5% vs 1%), more grade iii/iv flu-like symptoms (5% vs 3%), and more grade iii/iv hyperglycemia (3% vs 1%). during the additional 4 courses of treatment with paclitaxel, 2 deaths (0.1%) were attributed to treatment. during paclitaxel treatment, grade iv neutropenia was reported for 15% of patients, grade ii/iii neurosensory toxicity for 15%, grade ii/iii myalgias for 23%, and alopecia for 46%. the incidences of severe hematologic toxicities, infections, mucositis, and cardiovascular events increased with higher doses of doxorubicin. breast cancer after failure of initial chemotherapy for the 458 patients who received single-agent paclitaxel in the phase 3 breast carcinoma study, the following table shows the incidence of important adverse events by treatment arm (each arm was administered by a 3-hour infusion). table 14. frequency a of important adverse events in the phase 3 study of breast cancer after failure of initial chemotherapy or within 6 months of adjuvant chemotherapy percent of patients 175/3 b (n=229) 135/3 b (n=229) bone marrow - neutropenia <2,000/mm 3 90 81 <500/mm 3 28 19 - thrombocytopenia <100,000/mm 3 11 7 <50,000/mm 3 3 2 - anemia <11 g/dl 55 47 <8 g/dl 4 2 - infections 23 15 - febrile neutropenia 2 2 hypersensitivity reaction c - all 36 31 - severe 0 <1 peripheral neuropathy - any symptoms 70 46 - severe symptoms 7 3 mucositis - any symptoms 23 17 - severe symptoms 3 <1 a based on worst course analysis. b paclitaxel dose in mg/m 2 /infusion duration in hours. c all patients received premedication. severe events are defined as at least grade iii toxicity. myelosuppression and peripheral neuropathy were dose related. there was one severe hypersensitivity reaction (hsr) observed at the dose of 135 mg/m 2 . first-line nsclc in combination in the study conducted by the eastern cooperative oncology group (ecog), patients were randomized to either paclitaxel (t) 135 mg/m 2 as a 24-hour infusion in combination with cisplatin (c) 75 mg/m 2 , paclitaxel (t) 250 mg/m 2 as a 24-hour infusion in combination with cisplatin (c) 75 mg/m 2 with g-csf support, or cisplatin (c) 75 mg/m 2 on day 1, followed by etoposide (vp) 100 mg/m 2 on days 1, 2, and 3 (control). the following table shows the incidence of important adverse events. table 15. frequency a of important adverse events in the phase 3 study for first-line nsclc percent of patients t135/24 b c75 (n=195) t250/24 c c75 (n=197) vp100 d c75 (n=196) bone marrow - neutropenia <2,000/mm 3 <500/mm 3 - thrombocytopenia
Adverse Reactions Table:
| Percent of Patients (n=812) |
---|
Bone Marrow - Neutropenia <2,000/mm3 <500/mm3 - Leukopenia <4,000/mm3 <1,000/mm3 - Thrombocytopenia <100,000/mm3 <50,000/mm3 - Anemia <11 g/dL <8 g/dL - Infections - Bleeding - Red Cell Transfusions - Platelet Transfusions | 90 52 90 17 20 7 78 16 30 14 25 2 |
Hypersensitivity Reactionb - All - Severe† | 41 2 |
Cardiovascular - Vital Sign Changesc - Bradycardia (n=537) - Hypotension (n=532) - Significant Cardiovascular Events | 3 12 1 |
Abnormal ECG - All Pts - Pts with normal baseline (n=559) | 23 14 |
Peripheral Neuropathy - Any symptoms - Severe symptoms† | 60 3 |
Myalgia/Arthralgia - Any symptoms - Severe symptoms† | 60 8 |
Gastrointestinal - Nausea and vomiting - Diarrhea - Mucositis | 52 38 31 |
Alopecia | 87 |
Hepatic (Pts with normal baseline and on study data) - Bilirubin elevations (n=765) - Alkaline phosphatase elevations (n=575) - AST (SGOT) elevations (n=591) | 7 22 19 |
Injection Site Reaction | 13 |
| Percent of Patients |
---|
Intergroup | GOG-111 |
---|
T175/3b c75c (n=339) | C750c c75c (n=336) | T135/24b c75c (n=196) | C750c c75c (n=213) |
---|
- Bone Marrow
| | | | |
- Neutropenia <2,000/mm3 | 91d | 95d | 96 | 92 |
<500/mm3 | 33d | 43d | 81d | 58d |
- Thrombocytopenia <100,000/mm3e | 21d | 33d | 26 | 30 |
<50,000/mm3 | 3d | 7d | 10 | 9 |
- Anemia <11 g/dLf | 96 | 97 | 88 | 86 |
<8 g/dL | 3d | 8d | 13 | 9 |
- Infections | 25 | 27 | 21 | 15 |
- Febrile Neutropenia | 4 | 7 | 15d | 4 d |
- Hypersensitivity Reaction
| | | | |
- All | 11d | 6d | 8d,g | 1d,g |
- Severe† | 1 | 1 | 3d,g | - d,g |
- Neurotoxicityh
| | | | |
- Any symptoms | 87d | 52d | 25 | 20 |
- Severe symptoms† | 21d | 2d | 3d | - d |
- Nausea and Vomiting
| | | | |
- Any symptoms | 88 | 93 | 65 | 69 |
- Severe symptoms† | 18 | 24 | 10 | 11 |
- Myalgia/Arthralgia
| | | | |
- Any symptoms | 60d | 27d | 9d | 2d |
- Severe symptoms† | 6d | 1d | 1 | - |
- Diarrhea
| | | | |
- Any symptoms | 37d | 29d | 16d | 8d |
- Severe symptoms† | 2 | 3 | 4 | 1 |
- Athenia
| | | | |
- Any symptoms | NC | NC | 17d | 10d |
- Severe symptoms† | NC | NC | 1 | 1 |
Alopecia | | | | |
- Any symptoms | 96d | 89d | 55d | 37d |
- Severe symptoms† | 51d | 21d | 6 | 8 |
| Percent of Patients |
---|
175/3b (n=95) | 175/24 b (n=105) | 135/3 b (n=98) | 135/24 b (n=105) |
---|
Bone Marrow - Neutropenia <2,000/mm3 <500/mm3 - Thrombocytopenia <100,000/mm3 <50,000/mm3 - Anemia <11 g/dL <8 g/dL - Infections | 78 27 4 1 84 11 26 | 98 75 18 7 90 12 29 | 78 14 8 2 68 6 20 | 98 67 6 1 88 10 18 |
Hypersensitivity Reactionc - All - Severe† | 41 2 | 45 0 | 38 2 | 45 1 |
Peripheral Neuropathy - Any symptoms - Severe symptoms† | 63 1 | 60 2 | 55 0 | 42 0 |
Mucositis - Any symptoms - Severe symptoms† | 17 0 | 35 3 | 21 0 | 25 2 |
| Percent of Patients |
Early Population | Total Population |
ACc (n=166) | ACc followed by Td (n=159) | ACc (n=1551) | ACc followed by Td (n=1570) |
- Bone Marrowe
| | | | |
- Neutropenia <500/mm3 | 79 | 76 | 48 | 50 |
- Thrombocytopenia <50,000/mm3 | 27 | 25 | 11 | 11 |
- Anemia <8 g/dL | 17 | 21 | 8 | 8 |
- Infections | 6 | 14 | 5 | 6 |
- Fever Without Infection | – | 3 | <1 | 1 |
- Hypersensitivity Reactionf
| 1 | 4 | 1 | 2 |
- Cardiovascular Events
| 1 | 2 | 1 | 2 |
- Neuromotor Toxicity
| 1 | 1 | <1 | 1 |
- Neurosensory Toxicity
| – | 3 | <1 | 3 |
- Myalgia/Arthralgia
| – | 2 | <1 | 2 |
- Nausea/Vomiting
| 13 | 18 | 8 | 9 |
- Mucositis
| 13 | 4 | 6 | 5 |
| Percent of Patients |
175/3b (n=229) | 135/3 b (n=229) |
- Bone Marrow
| | |
- Neutropenia <2,000/mm3 | 90 | 81 |
<500/mm3 | 28 | 19 |
- Thrombocytopenia <100,000/mm3 | 11 | 7 |
<50,000/mm3 | 3 | 2 |
- Anemia <11 g/dL | 55 | 47 |
<8 g/dL | 4 | 2 |
- Infections | 23 | 15 |
- Febrile Neutropenia | 2 | 2 |
- Hypersensitivity Reactionc
| | |
- All | 36 | 31 |
- Severe† | 0 | <1 |
- Peripheral Neuropathy
| | |
- Any symptoms | 70 | 46 |
- Severe symptoms† | 7 | 3 |
- Mucositis
| | |
- Any symptoms | 23 | 17 |
- Severe symptoms† | 3 | <1 |
| Percent of Patients |
T135/24b c75 (n=195) | T250/24 c c75 (n=197) | VP100 d c75 (n=196) |
- Bone Marrow
- Neutropenia <2,000/mm3 <500/mm3 - Thrombocytopenia <normal <50,000/mm3 - Anemia <normal <8 g/dL - Infections | 89 74e 48 6 94 22 38 | 86 65 68 12 96 19 31 | 84 55 62 16 95 28 35 |
- Hypersensitivity Reactionf
- All - Severe† | 16 1 | 27 4e | 13 1 |
- Arthralgia/Myalgia
- Any symptoms - Severe symptoms† | 21e 3 | 42e 11 | 9 1 |
- Nausea/Vomiting
- Any symptoms - Severe symptoms† | 85 27 | 87 29 | 81 22 |
- Mucositis
- Any symptoms - Severe symptoms† | 18 1 | 28 4 | 16 2 |
- Neuromotor Toxicity
- Any symptoms - Severe symptoms† | 37 6 | 47 12 | 44 7 |
- Neurosensory Toxicity
- Any symptoms - Severe symptoms† | 48 13 | 61 28e | 25 8 |
- Cardiovascular Events
- Any symptoms - Severe symptoms† | 33 13 | 39 12 | 24 8 |
| Percent of Patients |
---|
Study CA139-174 Paclitaxel 135/3b q 3 wk (n=29) | Study CA139-281 Paclitaxel 100/3 b q 2 wk (n=56) |
---|
Bone Marrow | | |
- Neutropenia <2,000/mm3 | 100 | 95 |
<500/mm3 | 76 | 35 |
- Thrombocytopenia <100,000/mm3 | 52 | 27 |
<50,000/mm3 | 17 | 5 |
- Anemia <11 g/dL | 86 | 73 |
<8 g/dL | 34 | 25 |
- Febrile Neutropenia | 55 | 9 |
Opportunistic Infection | | |
- Any | 76 | 54 |
- Cytomegalovirus | 45 | 27 |
- Herpes Simplex | 38 | 11 |
- Pneumocystis carinii | 14 | 21 |
- M. avinum intracellulare | 24 | 4 |
- Candidiasis, esophageal | 7 | 9 |
- Cryptosporidiosis | 7 | 7 |
- Cryptococcal meningitis | 3 | 2 |
- Leukoencephalopathy | – | 2 |
Hypersensitivity Reactionc | | |
- All | 14 | 9 |
Cardiovascular | | |
- Hypotension | 17 | 9 |
- Bradycardia | 3 | - |
Peripheral Neuropathy | | |
- Any | 79 | 46 |
- Severe† | 10 | 2 |
Myalgia/Arthralgia | | |
- Any | 93 | 48 |
- Severe† | 14 | 16 |
Gastrointestinal | | |
- Nausea and Vomiting | 69 | 70 |
- Diarrhea | 90 | 73 |
- Mucositis | 45 | 20 |
Renal (creatinine elevation) | | |
- Any | 34 | 18 |
- Severe† | 7 | 5 |
Discontinuation for drug toxicity | 7 | 16 |
Drug Interactions:
Drug interactions in a phase 1 trial using escalating doses of paclitaxel (110 to 200 mg/m 2 ) and cisplatin (50 or 75 mg/m 2 ) given as sequential infusions, myelosuppression was more profound when paclitaxel was given after cisplatin than with the alternate sequence (i.e., paclitaxel before cisplatin). pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when paclitaxel was administered following cisplatin. the metabolism of paclitaxel is catalyzed by cytochrome p450 isoenzymes cyp2c8 and cyp3a4. caution should be exercised when administering paclitaxel concomitantly with known substrates or inhibitors of the cytochrome p450 isoenzymes ctp2c8 and cyp3a4. caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g., midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoc
Read more...onazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of cyp3a4. (see clinical pharmacology ). caution should also be exercised when paclitaxel is concomitantly administered with known substrates (e.g., repaglinide and rosiglitazone), inhibitors (e.g., gemfibrozil), and inducers (e.g., rifampin) of cyp2c8. (see clinical pharmacology ). potential interactions between paclitaxel, a substrate of cyp3a4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of cyp3a4, have not been evaluated in clinical trials. reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
Use in Pregnancy:
Pregnancy (see warnings section).
Pediatric Use:
Pediatric use the safety and effectiveness of paclitaxel in pediatric patients have not been established. there have been reports of central nervous system (cns) toxicity (rarely associated with death) in a clinical trial in pediatric patients in which paclitaxel was infused intravenously over 3 hours at doses ranging from 350 mg/m 2 to 420 mg/m 2 . the toxicity is most likely attributable to the high dose of the ethanol component of the paclitaxel vehicle given over a short infusion time. the use of concomitant antihistamines may intensify this effect. although a direct effect of the paclitaxel itself cannot be discounted, the high doses used in this study (over twice the recommended adult dosage) must be considered in assessing the safety of paclitaxel for use in this population.
Geriatric Use:
Geriatric use of 2228 patients who received paclitaxel in 8 clinical studies evaluating its safety and effectiveness in the treatment of advanced ovarian cancer, breast carcinoma, or nsclc, and 1,570 patients who were randomized to receive paclitaxel in the adjuvant breast cancer study, 649 patients (17%) were 65 years or older and 49 patients (1%) were 75 years or older. in most studies, severe myelosuppression was more frequent in elderly patients; in some studies, severe neuropathy was more common in elderly patients. in 2 clinical studies in nsclc, the elderly patients treated with paclitaxel had a higher incidence of cardiovascular events. estimates of efficacy appeared similar in elderly patients and in younger patients; however, comparative efficacy cannot be determined with confidence due to the small number of elderly patients studied. in a study of first-line treatment of ovarian cancer, elderly patients had a lower median survival than younger patients, but no other efficacy parameters favored the younger group. table 9 presents the incidences of grade iv neutropenia and severe neuropathy in clinical studies according to age. table 9. selected adverse events in geriatric patients receiving paclitaxel in clinical studies patients (n/total [%]) neutropenia (grade iv) peripheral neuropathy (grades iii/iv) indication age (y) age (y) (study/regimen) ?65 <65 ?65 <65 ovarian cancer (intergroup first-line/t175/3 c75 a ) 34/83 (41) 78/252 (31) 24/84(29)* b 46/255 (18) b (gog-111 first-line/t135/24 c75 a ) 48/61 (79) 106/129 (82) 3/62 (5) 2/134 (1) (phase 3 second-line/t175/3 c ) 5/19 (26) 21/76 (28) 1/19 (5) 0/76 (0) (phase 3 second-line/t175/24 c ) 21/25 (84) 57/79 (72) 0/25 (0) 2/80 (3) (phase 3 second-line/t135/3 c ) 4/16 (25) 10/81 (12) 0/17 (0) 0/81 (0) (phase 3 second-line/t135/24 c ) 17/22 (77) 53/83 (64) 0/22 (0) 0/83 (0) (phase 3 second-line pooled) 47/82 (57)* 141/319 (44) 1/83 (1) 2/320 (1) adjuvant breast cancer (intergroup/ac followed by t d ) 56/102 (55) 734/1468 (50) 5/102 (5) e 46/1468 (3) e breast cancer after failure of initial therapy (phase 3/t175/3 c ) 7/24 (29) 56/200 (28) 3/25 (12) 12/204 (6) (phase 3/t135/3 c ) 7/20 (35) 37/207 (18) 0/20 (0) 6/209 (3) non-small cell lung cancer (ecog/t135/24 c75 a ) 58/71 (82) 86/124 (69) 9/71 (13) f 16/124 (13) f (phase 3/t175/3 c80 a ) 37/89 (42)* 56/267 (21) 11/91 (12)* 11/271 (4) * p<0.05 a paclitaxel dose in mg/m 2 /infusion duration in hours; cisplatin doses in mg/m 2 . b peripheral neuropathy was included within the neurotoxicity category in the intergroup first-line ovarian cancer study (see table 11 ). c paclitaxel dose in mg/m 2 /infusion duration in hours. d paclitaxel (t) following 4 courses of doxorubicin and cyclophosphamide (ac) at a dose of 175 mg/m 2 /3 hours every 3 weeks for 4 courses. e peripheral neuropathy reported as neurosensory toxicity in the intergroup adjuvant breast cancer study (see table 13 ). f peripheral neuropathy reported as neurosensory toxicity in the ecog nsclc study (see table 15 ). information for patients: (see patient information leaflet ).
Overdosage:
Overdosage there is no known antidote for paclitaxel overdosage. the primary anticipated complications of overdosage would consist of bone marrow suppression, peripheral neurotoxicity, and mucositis. overdoses in pediatric patients may be associated with acute ethanol toxicity (see precautions, pediatric use ).
Description:
Description paclitaxel injection, usp is a clear, colorless to slightly yellow viscous solution. it is supplied as a nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. paclitaxel injection, usp is available in 30 mg (5 ml), 100 mg (16.7 ml), and 300 mg (50 ml) multidose vials. each ml of sterile nonpyrogenic solution contains 6 mg paclitaxel, usp, 527 mg of polyoxyl 35 castor oil, nf and 49.7% (v/v) dehydrated alcohol, usp and 2 mg citric acid, usp. paclitaxel is a natural product with antitumor activity. paclitaxel is obtained via a semi-synthetic process from taxus baccata . the chemical name for paclitaxel is 5?,20-epoxy-1,2?,4,7?, 10?,13?-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2r,3s)-n-benzoyl-3-phenylisoserine. paclitaxel has the following structural formula: paclitaxel, usp is a white to off-white crystalline powder with the empirical formula c 47 h 51 no 14 and a molecular weight of 853.9. it is highly lipophilic, insoluble in water, and melts at around 216° to 217°c. paclitaxel-str
Clinical Pharmacology:
Clinical pharmacology paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. this stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. in addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a biphasic manner. the initial rapid decline represents distribution to the peripheral compartment and elimination of the drug. the later phase is due, in part, to a relatively slow efflux of paclitaxel from the peripheral compartment. pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levels of 135 and 175 mg/m 2 were determined in
Read more... a phase 3 randomized study in ovarian cancer patients and are summarized in the following table: table 1. summary of pharmacokinetic parametersmean values dose (mg/m 2 ) infusion duration (h) n (patients) c max (ng/ml) auc (0-?) (ngh/ml) t-half (h) cl t (l/h/m 2 ) 135 24 2 195 6,300 52.7 21.7 175 24 4 365 7,993 15.7 23.8 135 3 7 2,170 7,952 13.1 17.7 175 3 5 3,650 15,007 20.2 12.2 c max = maximum plasma concentration auc (0 ?) = area under the plasma concentration-time curve from time 0 to infinity cl t = total body clearance it appeared that with the 24-hour infusion of paclitaxel, a 30% increase in dose (135 mg/m 2 vs 175 mg/m 2 ) increased the cmax by 87%, whereas the auc (0-?) remained proportional. however, with a 3- hour infusion, for a 30% increase in dose, the cmax and auc (0-?) were increased by 68% and 89%, respectively. the mean apparent volume of distribution at steady state, with the 24-hour infusion of paclitaxel, ranged from 227 to 688 l/m 2 , indicating extensive extravascular distribution and/or tissue binding of paclitaxel. the pharmacokinetics of paclitaxel were also evaluated in adult cancer patients who received single doses of 15 to 135 mg/m 2 given by 1-hour infusions (n=15), 30 to 275 mg/m 2 given by 6-hour infusions (n=36), and 200 to 275 mg/m 2 given by 24-hour infusions (n=54) in phase 1 and 2 studies. values for clt and volume of distribution were consistent with the findings in the phase 3 study. the pharmacokinetics of paclitaxel in patients with aids-related kaposi's sarcoma have not been studied. in vitro studies of binding to human serum proteins, using paclitaxel concentrations ranging from 0.1 to 50 mcg/ml, indicate that between 89 to 98% of drug is bound; the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel. after intravenous administration of 15 to 275 mg/m 2 doses of paclitaxel as 1-, 6-, or 24-hour infusions, mean values for cumulative urinary recovery of unchanged drug ranged from 1.3% to 12.6% of the dose, indicating extensive non-renal clearance. in 5 patients administered a 225 or 250 mg/m 2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine. total recovery of radioactivity ranged from 56% to 101% of the dose. paclitaxel represented a mean of 5% of the administered radioactivity recovered in the feces, while metabolites, primarily 6?-hydroxypaclitaxel, accounted for the balance. in vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6?-hydroxypaclitaxel by the cytochrome p450 isozyme cyp2c8; and to 2 minor metabolites, 3'- p -hydroxypaclitaxel and 6?, 3'- p -dihydroxypaclitaxel, by cyp3a4. in vitro , the metabolism of paclitaxel to 6?-hydroxypaclitaxel was inhibited by a number of agents (ketoconazole, verapamil, diazepam, quinidine, dexamethasone, cyclosporin, teniposide, etoposide, and vincristine), but the concentrations used exceeded those found in vivo following normal therapeutic doses. testosterone, 17?-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of cyp2c8, also inhibited the formation of 6?-hydroxypaclitaxel in vitro . the pharmacokinetics of paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of cyp2c8 and/or cyp3a4 (see precautions, drug interactions ). the disposition and toxicity of paclitaxel 3-hour infusion were evaluated in 35 patients with varying degrees of hepatic function. relative to patients with normal bilirubin, plasma paclitaxel exposure in patients with abnormal serum bilirubin ?2 times upper limit of normal (uln) administered 175 mg/m 2 was increased, but with no apparent increase in the frequency or severity of toxicity. in 5 patients with serum total bilirubin >2 times uln, there was a statistically nonsignificant higher incidence of severe myelosuppression, even at a reduced dose (110 mg/m 2 ), but no observed increase in plasma exposure (see precautions, hepatic and dosage and administration ). the effect of renal or hepatic dysfunction on the disposition of paclitaxel has not been investigated. possible interactions of paclitaxel with concomitantly administered medications have not been formally investigated.
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility the carcinogenic potential of paclitaxel has not been studied. paclitaxel has been shown to be clastogenic in vitro (chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice). paclitaxel was not mutagenic in the ames test of the cho/hgprt gene mutation assay. administration of paclitaxel prior to and during mating produced impairment of fertility in male and female rats at doses equal to or greater than 1 mg/kg/day (about 0.04 the daily maximum recommended human dose on a mg/m 2 basis). at this dose, paclitaxel caused reduced fertility and reproductive indices, and increased embryo- and fetotoxicity. (see warnings ).
Clinical Studies:
Clinical studies ovarian carcinoma first-line data the safety and efficacy of paclitaxel followed by cisplatin in patients with advanced ovarian cancer and no prior chemotherapy were evaluated in 2, phase 3 multicenter, randomized, controlled trials. in an intergroup study led by the european organization for research and treatment of cancer involving the scandinavian group nocova, the national cancer institute of canada, and the scottish group, 680 patients with stage ii bc , iii, or iv disease (optimally or non-optimally debulked) received either paclitaxel 175 mg/m 2 infused over 3 hours followed by cisplatin 75 mg/m 2 (tc) or cyclophosphamide 750 mg/m 2 followed by cisplatin 75 mg/m 2 (cc) for a median of 6 courses. although the protocol allowed further therapy, only 15% received both drugs for 9 or more courses. in a study conducted by the gynecological oncology group (gog), 410 patients with stage iii or iv disease (>1 cm residual disease after staging laparotomy or distant met
Read more...astases) received either paclitaxel 135 mg/m 2 infused over 24 hours followed by cisplatin 75 mg/m 2 or cyclophosphamide 750 mg/m 2 followed by cisplatin 75 mg/m 2 for 6 courses. in both studies, patients treated with paclitaxel in combination with cisplatin had significantly higher response rate, longer time to progression, and longer survival time compared with standard therapy. these differences were also significant for the subset of patients in the intergroup study with non- optimally debulked disease, although the study was not fully powered for subset analyses ( tables 2a and 2b ). kaplan- meier survival curves for each study are shown in figures 1 and 2 . table 2a. efficacy in the phase 3 first-line ovarian carcinoma studies intergroup (non-optimally debulked subset) gog-111 t175/3 a c75 (n=218) c750 a c75 (n=227) t135/24 a c75 (n=196) c750 a c75 (n=214) clinical response b (n=153) (n=153) (n=113) (n=127) - rate (percent) 58 43 62 48 - p-value c 0.016 0.04 time to progression - median (months) 13.2 9.9 16.6 13.0 - p-value c 0.0060 0.0008 - hazard ratio (hr) c 0.76 0.70 - 95% ci c 0.62 to 0.92 0.56 to 0.86 survival - median (months) 29.5 21.9 35.5 24.2 - p-value c 0.0057 0.0002 - hazard ratio (hr) c 0.73 0.64 - 95% ci c 0.58 to 0.91 0.50 to 0.81 a paclitaxel dose in mg/m 2 /infusion duration in hours; cyclophosphamide and cisplatin doses in mg/m 2 . b among patients with measurable disease only. c unstratified for the intergroup study, stratified for study gog-111. table 2b. efficacy in the phase 3 first-line ovarian carcinoma intergroup study t175/3 a c75 (n=342) c750 a c75 (n=338) clinical response b (n=162) (n=161) - rate (percent) 59 45 - p-value c 0.014 time to progression - median (months) 15.3 11.5 - p-value c 0.0005 - hazard ratio (hr) c 0.74 - 95% ci c 0.63 to 0.88 survival - median (months) 35.6 25.9 - p-value c 0.0016 - hazard ratio (hr) c 0.73 - 95% ci c 0.60 to 0.89 a paclitaxel dose in mg/m 2 /infusion duration in hours; cyclophosphamide and cisplatin doses in mg/m 2 . b among patients with measurable disease only. c unstratified. figure 1. survival: cc versus tc (intergroup) figure 2. survival: cc versus tc (gog-111) the adverse event profile for patients receiving paclitaxel in combination with cisplatin in these studies was qualitatively consistent with that seen for the pooled analysis of data from 812 patients treated with single-agent paclitaxel in 10 clinical studies. these adverse events and adverse events from the phase 3 first-line ovarian carcinoma studies are described in the adverse reactions section in tabular ( tables 10 and 11 ) and narrative form. second-line data data from five phase 1 and 2 clinical studies (189 patients), a multicenter randomized phase 3 study (407 patients), as well as an interim analysis of data from more than 300 patients enrolled in a treatment referral center program were used in support of the use of paclitaxel in patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary. two of the phase 2 studies (92 patients) utilized an initial dose of 135 to 170 mg/m 2 in most patients (>90%) administered over 24 hours by continuous infusion. response rates in these two studies were 22% (95% ci, 11% to 37%) and 30% (95% ci, 18% to 46%) with a total of 6 complete and 18 partial responses in 92 patients. the median duration of overall response in these two studies measured from the first day of treatment was 7.2 months (range, 3.5 to 15.8 months) and 7.5 months (range, 5.3 to 17.4 months), respectively. the median survival was 8.1 months (range, 0.2 to 36.7 months) and 15.9 months (range, 1.8 to 34.5+ months). the phase 3 study had a bifactorial design and compared the efficacy and safety of paclitaxel, administered at 2 different doses (135 or 175 mg/m 2 ) and schedules (3- or 24-hour infusion). the overall response rate for the 407 patients was 16.2% (95% ci, 12.8% to 20.2%), with 6 complete and 60 partial responses. duration of response, measured from the first day of treatment was 8.3 months (range, 3.2 to 21.6 months). median time to progression was 3.7 months (range, 0.1+ to 25.1+ months). median survival was 11.5 months (range, 0.2 to 26.3+ months). response rates, median survival, and median time to progression for the 4 arms are given in the following table. table 3. efficacy in the phase 3 second-line ovarian carcinoma study 175/3 (n=96) 175/24 (n=106) 135/3 (n=99) 135/24 (n=106) response - rate (percent) 14.6 21.7 15.2 13.2 - 95% confidence interval (8.5 to 23.6) (14.5 to 31) (9 to 24.1) (7.7 to 21.5) time to progression - median (months) 4.4 4.2 3.4 2.8 - 95% confidence interval (3.0 to 5.6) (3.5 to 5.1) (2.8 to 4.2) (1.9 to 4) survival - median (months) 11.5 11.8 13.1 10.7 - 95% confidence interval (8.4 to 14.4) (8.9 to 14.6) (9.1 to 14.6) (8.1 to 13.6) analyses were performed as planned by the bifactorial study design described in the protocol, by comparing the 2 doses (135 or 175 mg/m 2 ) irrespective of the schedule (3 or 24 hours) and the two schedules irrespective of dose. patients receiving the 175 mg/m 2 dose had a response rate similar to that for those receiving the 135 mg/m 2 dose: 18% versus 14% (p=0.28). no difference in response rate was detected when comparing the 3-hour with the 24-hour infusion: 15% versus 17% (p=0.50). patients receiving the 175 mg/m 2 dose of paclitaxel had a longer time to progression than those receiving the 135 mg/m 2 dose: median 4.2 versus 3.1 months (p=0.03). the median time to progression for patients receiving the 3-hour versus the 24-hour infusion was 4.0 months versus 3.7 months, respectively. median survival was 11.6 months in patients receiving the 175 mg/m 2 dose of paclitaxel and 11.0 months in patients receiving the 135 mg/m 2 dose (p=0.92). median survival was 11.7 months for patients receiving the 3-hour infusion of paclitaxel and 11.2 months for patients receiving the 24 hour infusion (p=0.91). these statistical analyses should be viewed with caution because of the multiple comparisons made. paclitaxel remained active in patients who had developed resistance to platinum-containing therapy (defined as tumor progression while on, or tumor relapse within 6 months from completion of, a platinum-containing regimen) with response rates of 14% in the phase 3 study and 31% in the phase 1 and 2 clinical studies. the adverse event profile in this phase 3 study was consistent with that seen for the pooled analysis of data from 812 patients treated in 10 clinical studies. these adverse events and adverse events from the phase 3 second-line ovarian carcinoma study are described in the adverse reactions section in tabular ( tables 10 and 12 ) and narrative form. the results of this randomized study support the use of paclitaxel at doses of 135 to 175 mg/m 2 , administered by a 3-hour intravenous infusion. the same doses administered by 24-hour infusion were more toxic. however, the study had insufficient power to determine whether a particular dose and schedule produced superior efficacy. breast carcinoma adjuvant therapy a phase 3 intergroup study (cancer and leukemia group b [calgb], eastern cooperative oncology group [ecog], north central cancer treatment group [ncctg], and southwest oncology group [swog]) randomized 3170 patients with node-positive breast carcinoma to adjuvant therapy with paclitaxel or to no further chemotherapy following 4 courses of doxorubicin and cyclophosphamide (ac). this multicenter trial was conducted in women with histologically positive lymph nodes following either a mastectomy or segmental mastectomy and nodal dissections. the 3 x 2 factorial study was designed to assess the efficacy and safety of 3 different dose levels of doxorubicin (a) and to evaluate the effect of the addition of paclitaxel administered following the completion of ac therapy. after stratification for the number of positive lymph nodes (1 to 3, 4 to 9, or 10+), patients were randomized to receive cyclophosphamide at a dose of 600 mg/m 2 and doxorubicin at doses of either 60 mg/m 2 (on day 1), 75 mg/m 2 (in 2 divided doses on days 1 and 2), or 90 mg/m 2 (in 2 divided doses on days 1 and 2 with prophylactic g-csf support and ciprofloxacin) every 3 weeks for 4 courses and either paclitaxel 175 mg/m 2 as a 3-hour infusion every 3 weeks for 4 additional courses or no additional chemotherapy. patients whose tumors were positive were to receive subsequent tamoxifen treatment (20 mg daily for 5 years); patients who received segmental mastectomies prior to study were to receive breast irradiation after recovery from treatment-related toxicities. at the time of the current analysis, median follow-up was 30.1 months. of the 2066 patients who were hormone receptor positive, 93% received tamoxifen. the primary analyses of disease-free survival and overall survival used multivariate cox models, which included paclitaxel administration, doxorubicin dose, number of positive lymph nodes, tumor size, menopausal status, and estrogen receptor status as factors. based on the model for disease-free survival, patients receiving ac followed by paclitaxel had a 22% reduction in the risk of disease recurrence compared to patients randomized to ac alone (hazard ratio [hr]=0.78, 95% ci, 0.67 to 0.91, p=0.0022). they also had a 26% reduction in the risk of death (hr=0.74, 95% ci, 0.60 to 0.92, p=0.0065). for disease-free survival and overall survival, p-values were not adjusted for interim analyses. kaplan-meier curves are shown in figures 3 and 4 . increasing the dose of doxorubicin higher than 60 mg/m 2 had no effect on either disease-free survival or overall survival. fugure 3. disease-free survival: ac versus ac+t fugure 4. survival: ac versus ac+t subset analyses subsets defined by variables of known prognostic importance in adjuvant breast carcinoma were examined, including number of positive lymph nodes, tumor size, hormone receptor status, and menopausal status. such analyses must be interpreted with care, as the most secure finding is the overall study result. in general, a reduction in hazard similar to the overall reduction was seen with paclitaxel for both disease-free and overall survival in all of the larger subsets with one exception; patients with receptor-positive tumors had a smaller reduction in hazard (hr=0.92) for disease-free survival with paclitaxel than other groups. results of subset analyses are shown in table 4 table 4. subset analyses adjuvant breast carcinoma study patient subset disease-free survival overall survival no. of patients no. of recurrences hazard ratio (95% ci) no. of deaths hazard ratio (95% ci) no. positive nodes 1 to 3 1,449 221 0.72 (0.55 to 0.94) 107 0.76 (0.52 to 1.12) 4 to 9 1,310 274 0.78 (0.61 to 0.99) 148 0.66 (0.47 to 0.91) 10+ 360 129 0.93 (0.66 to 1.31) 87 0.90 (0.59 to 1.36) tumor size (cm) ?2 1,096 153 0.79 (0.57 to 1.08) 67 0.73 (0.45 to 1.18) >2 and ?5 1,611 358 0.79 (0.64 to 0.97) 201 0.74 (0.56 to 0.98) >5 397 111 0.75 (0.51 to 1.08) 72 0.73 (0.46 to 1.16) menopausal status pre 1,929 374 0.83 (0.67 to 1.01) 187 0.72 (0.54 to 0.97) post 1,183 250 0.73 (0.57 to 0.93) 155 0.77 (0.56 to 1.06) receptor status positive a 2,066 293 0.92 (0.73 to 1.16) 126 0.83 (0.59 to 1.18) negative/unknown b 1,055 331 0.68 (0.55 to 0.85) 216 0.71 (0.54 to 0.93) a positive for either estrogen or progesterone receptors. b negative or missing for both estrogen and progesterone receptors (both missing: n=15). these retrospective subgroup analyses suggest that the beneficial effect of paclitaxel is clearly established in the receptor-negative subgroup, but the benefit in receptor-positive patients is not yet clear. with respect to menopausal status, the benefit of paclitaxel is consistent (see table 4 and figures 5 to 8 ). figure 5. disease-free survival: receptor status negative / unknown ac versus ac+t f igure 6. disease-free survivalreceptor status positive ac versus ac+t f igure 7. disease-free survivalpremenopausal ac versus ac+t figure 8. disease-free survival: postmenopausal ac versus ac+t the adverse event profile for the patients who received paclitaxel subsequent to ac was consistent with that seen in the pooled analysis of data from 812 patients ( table 10 ) treated with single-agent paclitaxel in 10 clinical studies. these adverse events are described in the adverse reactions section in tabular ( tables 10 and 13 ) and narrative form. after failure of initial chemotherapy data from 83 patients accrued in three, phase 2 open-label studies and from 471 patients enrolled in a phase 3 randomized study were available to support the use of paclitaxel in patients with metastatic breast carcinoma. phase 2 open label studies two studies were conducted in 53 patients previously treated with a maximum of one prior chemotherapeutic regimen. paclitaxel was administered in these 2 trials as a 24-hour infusion at initial doses of 250 mg/m 2 (with g-csf support) or 200 mg/m 2 . the response rates were 57% (95% ci: 37% to 75%) and 52% (95% ci: 32% to 72%), respectively. the third phase 2 study was conducted in extensively pretreated patients who had failed anthracycline therapy and who had received a minimum of 2 chemotherapy regimens for the treatment of metastatic disease. the dose of paclitaxel was 200 mg/m2 as a 24-hour infusion with g-csf support. nine of 30 patients achieved a partial response, for a response rate of 30% (95% ci: 15% to 50%). phase 3 randomized study this multicenter trial was conducted in patients previously treated with 1 or 2 regimens of chemotherapy. patients were randomized to receive paclitaxel at a dose of either 175 mg/m 2 or 135 mg/m 2 given as a 3-hour infusion. in the 471 patients enrolled, 60% had symptomatic disease with impaired performance status at study entry, and 73% had visceral metastases. these patients had failed prior chemotherapy either in the adjuvant setting (30%), the metastatic setting (39%), or both (31%). sixty-seven percent of the patients had been previously exposed to anthracyclines and 23% of them had disease considered resistant to this class of agents. the overall response rate for the 454 evaluable patients was 26% (95% ci, 22% to 30%), with 17 complete and 99 partial responses. the median duration of response, measured from the first day of treatment, was 8.1 months (range, 3.4 to 18.1+ months). overall for the 471 patients, the median time to progression was 3.5 months (range, 0.03 to 17.1 months). median survival was 11.7 months (range, 0 to 18.9 months). response rates, median survival and median time to progression for the 2 arms are given in the following table. table 5. efficacy in breast cancer after failure of initial chemotherapy or within 6 months of adjuvant chemotherapy 175/3 (n=235) 135/3 (n=236) response - rate (percent) - p-value 28 0.135 22 time to progression - median (months) - p-value 4.2 0.027 3 survival - median (months) - p-value 11.7 0.321 10.5 the adverse event profile of the patients who received single-agent paclitaxel in the phase 3 study was consistent with that seen for the pooled analysis of data from 812 patients treated in 10 clinical studies. these adverse events and adverse events from the phase 3 breast carcinoma study are described in the adverse reactions section in tabular ( tables 10 and 14 ) and narrative form. non-small cell lung carcinoma (nsclc) in a phase 3 open-label randomized study conducted by the ecog, 599 patients were randomized to either paclitaxel (t) 135 mg/m 2 as a 24-hour infusion in combination with cisplatin (c) 75 mg/m 2 , paclitaxel (t) 250 mg/m 2 as a 24-hour infusion in combination with cisplatin (c) 75 mg/m 2 with g-csf support, or cisplatin (c) 75 mg/m 2 on day 1, followed by etoposide (vp) 100 mg/m 2 on days 1, 2, and 3 (control). response rates, median time to progression, median survival, and 1-year survival rates are given in the following table. the reported p-values have not been adjusted for multiple comparisons. there were statistically significant differences favoring each of the paclitaxel plus cisplatin arms for response rate and time to tumor progression. there was no statistically significant difference in survival between either paclitaxel plus cisplatin arm and the cisplatin plus etoposide arm. table 6. efficacy parameters in the phase 3 first-line nsclc study t135/24 c75 (n=198) t250/24 c75 (n=201) vp100 a c75 (n=200) response - rate (percent) 25 23 12 - p-value b 0.001 <0.001 time to progression - median (months) 4.3 4.9 2.7 - p-value b 0.05 0.004 survival - median (months) 9.3 10 7.4 - p-value b 0.12 0.08 1-year survival - percent of patients 36 40 32 a etoposide (vp) 100 mg/m 2 was administered iv on days 1, 2, and 3. b compared to cisplatin/etoposide. in the ecog study, the functional assessment of cancer therapy-lung (fact-l) questionnaire had 7 subscales that measured subjective assessment of treatment. of the 7, the lung cancer specific symptoms subscale favored the paclitaxel 135 mg/m 2 /24 hour plus cisplatin arm compared to the cisplatin/etoposide arm. for all other factors, there was no difference in the treatment groups. the adverse event profile for patients who received paclitaxel in combination with cisplatin in this study was generally consistent with that seen for the pooled analysis of data from 812 patients treated with single-agent paclitaxel in 10 clinical studies. these adverse events and adverse events from the phase 3 first-line nsclc study are described in the adverse reactions section in tabular ( tables 10 and 15 ) and narrative form. aids-related kaposis sarcoma data from 2, phase 2 open-label studies support the use of paclitaxel as second-line therapy in patients with aids-related kaposis sarcoma. fifty-nine of the 85 patients enrolled in these studies had previously received systemic therapy, including interferon alpha (32%), daunoxome® (31%), doxil® (2%), and doxorubicin containing chemotherapy (42%), with 64% having received prior anthracyclines. eighty-five percent of the pretreated patients had progressed on, or could not tolerate, prior systemic therapy. 1 in study ca139-174, patients received paclitaxel at 135 mg/m 2 as a 3-hour infusion every 3 weeks (intended dose intensity 45 mg/m 2 /week). if no dose-limiting toxicity was observed, patients were to receive 155 mg/m 2 and 175 mg/m 2 in subsequent courses. hematopoietic growth factors were not to be used initially. in study ca139-281, patients received paclitaxel at 100 mg/m 2 as a 3-hour infusion every 2 weeks (intended dose intensity 50 mg/m 2 /week). in this study patients could be receiving hematopoietic growth factors before the start of paclitaxel therapy, or this support was to be initiated as indicated; the dose of paclitaxel was not increased. the dose intensity of paclitaxel used in this patient population was lower than the dose intensity recommended for other solid tumors. all patients had widespread and poor-risk disease. applying the actg staging criteria to patients with prior systemic therapy, 93% were poor risk for extent of disease (t1), 88% had a cd4 count <200 cells/mm 3 (i1), and 97% had poor risk considering their systemic illness (s1). all patients in study ca139-174 had a karnofsky performance status of 80 or 90 at baseline; in study ca139-281, there were 26 (46%) patients with a karnofsky performance status of 70 or worse at baseline. table 7. extent of disease at study entry percent of patients prior systemic therapy (n=59) visceral ± edema ± oral ± cutaneous 42 edema or lymph nodes ± oral ± cutaneous 41 oral ± cutaneous 10 cutaneous only 7 although the planned dose intensity in the 2 studies was slightly different (45 mg/m 2 /week in study ca139-174 and 50 mg/m 2 /week in study ca139-281), delivered dose intensity was 38 to 39 mg/m 2 /week in both studies, with a similar range (20 to 24 to 51 to 61). efficacy the efficacy of paclitaxel was evaluated by assessing cutaneous tumor response according to the amended actg criteria and by seeking evidence of clinical benefit in patients in 6 domains of symptoms and/or conditions that are commonly related to aids-related kaposis sarcoma. cutaneous tumor response (amended actg criteria) the objective response rate was 59% (95% ci, 46 to 72%) (35 of 59 patients) in patients with prior systemic therapy. cutaneous responses were primarily defined as flattening of more than 50% of previously raised lesions. table 8. overall best response (amended actg criteria) percent of patients prior systemic therapy (n=59) complete response 3 partial response 56 stable disease 29 progression 8 early death/toxicity 3 the median time to response was 8.1 weeks and the median duration of response measured from the first day of treatment was 10.4 months (95% ci, 7.0 to 11.0 months) for the patients who had previously received systemic therapy. the median time to progression was 6.2 months (95% ci, 4.6 to 8.7 months). additional clinical benefit most data on patient benefit were assessed retrospectively (plans for such analyses were not included in the study protocols). nonetheless, clinical descriptions and photographs indicated clear benefit in some patients, including instances of improved pulmonary function in patients with pulmonary involvement, improved ambulation, resolution of ulcers, and decreased analgesic requirements in patients with kaposis sarcoma (ks) involving the feet and resolution of facial lesions and edema in patients with ks involving the face, extremities, and genitalia. safety the adverse event profile of paclitaxel administered to patients with advanced hiv disease and poor-risk aids-related kaposis sarcoma was generally similar to that seen in the pooled analysis of data from 812 patients with solid tumors. these adverse events and adverse events from the phase 2 second-line kaposis sarcoma studies are described in the adverse reactions section in tabular ( tables 10 and 16 ) and narrative form. in this immunosuppressed patient population, however, a lower dose intensity of paclitaxel and supportive therapy including hematopoietic growth factors in patients with severe neutropenia are recommended. patients with aids-related kaposis sarcoma may have more severe hematologic toxicities than patients with solid tumors. paclitaxel-1figure paclitaxel-2figure paclitaxel-3figure paclitaxel-4figure paclitaxel-5figure paclitaxel-6figure paclitaxel-7figure paclitaxel-8figure
How Supplied:
How supplied paclitaxel injection, usp (6 mg/ml) is a clear, colorless to slightly yellow viscous solution and supplied as follows: ndc 62332-620-05 30 mg/5 ml multidose vial individually packaged in a carton. ndc 62332-621-17 100 mg/16.7 ml multidose vial individually packaged in a carton. ndc 62332-622-50 300 mg/50 ml multidose vial individually packaged in a carton. storage store the vials in original cartons between 20° to 25°c (68° to 77°f). [see usp controlled room temperature]. retain in the original package to protect from light. handling and disposal see dosage and administration, preparation and administration precautions.
Package Label Principal Display Panel:
Package label.principal display panel paclitaxel injection usp, 30 mg/vial - vial label paclitaxel injection usp, 30 mg/vial - carton label paclitaxel injection usp, 100 mg/vial - vial label paclitaxel injection usp, 100 mg/vial - carton label paclitaxel injection usp, 300 mg/vial - vial label paclitaxel injection usp, 300 mg/vial - carton label paclitaxel-30mg-vial-label paclitaxel-30mg-carton-label paclitaxel-100mg-vial-label paclitaxel-100mg-carton-label paclitaxel-300mg-vial-label paclitaxel-300mg-carton-label